Apartment market moving on up Oct 22, 2009
Two other biotech companies in the top 10 are Emeryville's Onyx Pharmaceuticals and Redwood City's Genomic Health Inc., along with Santa Clara data deduplication company Data Domain, recently snapped up by EMC Corp., and San Jose networking company Force10 Networks Inc.. At No. 1, with a 146,050 percent growth rate is Woodland Hills' (Los Angeles County) ReachLocal, an online advertising platform provider. (San Francisco Chronicle)
Venture watch: FilmAngels, Good Data, Proteolix Oct 16, 2009
-- Proteolix Inc., which raised $142 million to develop new proteasome inhibitors for cancer, has agreed to be acquired by publicly traded Onyx Pharmaceuticals Inc. for up to $851 million. Cancer cells are more susceptible to cell death when the proteasome is inhibited. (San Francisco Chronicle -- Business)
Onyx Pharmaceuticals Oct 13, 2009
Local Search Site Search. THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING. (Boston Globe)
Onyx Pharma Will Pay up to $851M for Proteolix Oct 13, 2009
Onyx Pharmaceuticals Inc. said Monday it will buy cancer drug developer Proteolix Inc. in a deal that could be worth as much as $851 million. Onyx shares advanced $1. (ABC News -- Wire)
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009 Sep 17, 2009
Nexavar is being co-developed by Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc. ... About Onyx Pharmaceuticals, Inc. ... Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. (PR Newswire)
Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference Sep 5, 2009
Sept. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ) today announced that it will present at the Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 14, at 10:55 a.m. Eastern Time ... Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer ... SOURCE Onyx Pharmaceuticals, Inc.. (PR Newswire)
Cytopia's CYT387 Receives FDA Clearance to Start US Clinical Trials Sep 4, 2009
A similar JAK2 inhibitor in clinical development was recently licensed by Onyx Pharmaceuticals for $550 million including a $25 million up-front payment and double-digit royalties. About Cytopia. (PR Newswire)
Onyx Pharma slides after analyst lowers rating Aug 11, 2009
NEW YORK Shares of Onyx Pharmaceuticals Inc. slipped Monday after an analyst downgraded the stock, saying Onyx's recent stock sale will probably be used to fund an expensive acquisition that will increase spending and reduce profits ... Onyx Pharmaceuticals Inc. (Yahoo News -- Pharmaceutical Industry News)
Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes Aug 7, 2009
Aug. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ) today announced that it has agreed to sell an aggregate of four million shares of its common stock at a price to the public of $30. 50 per share and $200 million aggregate principal amount of its 4. (PR Newswire)
Onyx Pharmaceuticals Files Complaint Against Bayer Corporation May 18, 2009
May 17 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ) today announced that it has filed a complaint in the United States District Court for the Northern District of California asserting its rights to a Phase 2 anti-cancer compound discovered during joint research between Onyx and Bayer ... About Onyx Pharmaceuticals, Inc. ... Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. (PR Newswire)
Onyx Sues Bayer Over Anti-Cancer Compound May 18, 2009
NEW YORK (Reuters) - Onyx Pharmaceuticals Inc said on Sunday it sued Bayer AG over its rights to an anti-cancer compound that it says it discovered during joint research with the German drugmaker. Onyx's lawsuit, filed in the U.S. District Court for the Northern District of California, seeks a declaration that fluoro-sorafenib is a jointly owned collaboration compound under an agreement between the two companies. (ABC News -- Wire)
Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting May 15, 2009
May 14 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ) today announced that more than 65 studies evaluating the use of Nexavar(R) (sorafenib) tablets will be presented at the 2009 American Society of Clinical Oncology (ASCO) annual meeting. "Nexavar has a proven track record in two cancers - in the treatment of unresectable hepatocellular carcinoma (HCC), or liver cancer, and in the treatment of advanced renal cell carcinoma (RCC), or... (PR Newswire)
Growth in All the Wrong Places May 9, 2009
The top line for Onyx Pharmaceuticals (Nasdaq: ONXX) should certainly be celebrated: A 17% increase in the sales of cancer drug Nexavar is nothing to sneeze at. But investors should be cautious about future growth and how much is going to trickle down to earnings. (MSNBC -- Business)
Vitamin K May Boost Effects of Cancer Pill Nexavar Apr 28, 2009
They said combining vitamin K with the cancer pill Nexavar or sorafenib sold by Onyx Pharmaceuticals Inc and German drugmaker Bayer AG helped it kill liver and pancreatic cancer in human cell cultures. "K vitamins ... appear to enhance the effects of sorafenib, thus requiring lower, less-toxic doses," Dr. Brian Carr of Thomas Jefferson University in Philadelphia said in a statement. (MEDLINEplus)
Quarterly Changes to the NASDAQ Q-50 Index Mar 16, 2009
The following twelve securities will be added to the Index: Career Education Corporation (NasdaqGS: - ), Cree, Inc. (NasdaqGS: - ), Itron Inc. (NasdaqGS: - ), LKQ Corporation (NasdaqGS: - ), Level 3 Communications, Inc. (NasdaqGS: - ), Mylan Inc. (NasdaqGS: - ), Netflix, Inc. (NasdaqGS: - ), ONYX Pharmaceuticals, Inc. (NasdaqGS: - ), Open Text Corporation (NasdaqGS: - ), Sepracor Inc. (NasdaqGS: - ), Thoratec Corporation (NasdaqGS: - ) and Tellabs, Inc. (NasdaqGS: - ). The Index is designed to... (Primezone Releases)
S*BIO Receives BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award Mar 6, 2009
" About BioSpectrum Launched in 2003 by Asia's leading specialty publishing company, CyberMedia India Ltd., BioSpectrum is India's and Asia-Pacific's most widely circulated and read Life Sciences media platform. It comes out in two monthly editions: India edition published from Banglaore and an Asian edition, printed and published from Singapore. The business-to-business magazine tracks the growth of life science companies, captures the emerging technological and entrepreneurial trends in the... (PR Newswire)
Update: Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results Feb 24, 2009
Feb. 23 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ) today reported its financial results for the full year and fourth quarter 2008 ... About Onyx Pharmaceuticals, Inc. ... Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). (PR Newswire)
Weekly business calendar Feb 23, 2009
-- Earnings reports expected from American Reprographics, iPass, Nordstrom, Onyx Pharmaceuticals. Get Quote. (San Francisco Chronicle -- Business)
